DIAsource ImmunoAssays® S.A.

We are proud to present the Biomex Network. Within the network, we are able to provide all necessary products and services that are needed to develop, validate, register and produce an IvD.
Biomex, founded in 1989, has over 25 years of experience in the delivery of human-based raw materials such as disease state plasma and patient samples. Over 95% of all delivered human materials are sourced in our donor centers in Heidelberg, Munich and Cameroon. In addition to the delivery of biological and clinical materials, Biomex also offers a spectrum of services, for example, assay validation or CE marking.

Medical Research Networx (MRN), our American affiliate, has an extensive network of Principal Investigators who perform biological sample collections of a broad range of patient popula- tions, including but not limited to infectious diseases, oncological, endocrinology, chronic diseases and normal. MRN’s network is capable of recruiting PI’s and providing administrative and regulatory assistance to develop protocol approved, client directed collections of any clinical population that are required from clients.

Biomex US is specialized in the production and delivery of an entire range of human serum from normal to flash frozen to AB male serum.

DiaMex, develops and produces plasma based manufacturer-independent multi-analyte serological controls. Aside from its own Optitrol portfolio, DiaMex also offers a wide range of tailor made serological controls.

ESfEQA, is an worldwide EQA program provider. Through the Biomex network, ESfEQA has the ability to supply an EQA scheme with samples that are most similar to patient samples.

Products
• Bulk plasma for production
• Residual patient samples
• Prospective sample collections
• Panels for R&D and QC
• Reagents for ELISA

We are proud to have a world-wide reach and to be the only company that covers all aspects of products and services needed for the R&D, QC and production of serological and NAT tests.

Cerba Research is the merge of Barc Lab, Histalim and Cerba Xpert. All 3 entities are part of the Cerba HealthCare group and have decided to join forces under one name.

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Starting with penicillin, our first product manufactured in 1955, our company produced hundreds of pharmaceutical substances. Today, Antibiotice is one of the most important Romanian producers of generic drugs.

What kind of pharmaceutical products do we produce?

Antibiotice develops and produces generic drugs for human use (157 products), veterinary drugs and the active ingredient Nystatin.

Our generic drugs are mainly intended to patients with infectious diseases, but also for cardiovascular, dermatological, digestive and central nervous system related pathologies.

Domestic and international market
We have been present with pharmaceutical products and Nystatin API in Romania and other 75 countries around the world. In terms of Nystatin active ingredient production, Antibiotice ranks first worldwide among the pharmaceutical manufacturers. In Romania we continue to be the main manufacturer of antiinfective generic drugs, a manufacturer with competitive medicines and affordable prices. Our medicines are delivered in hospitals – especially the antiinfectives – contributing overall to significant savings for the Romanian healthcare system.

Quality standards

Our continuous development and expansion on international markets were possible through consistent investments and implementation of internationally recognized quality standards::

• Good Manufacturing Practice (EU-GMP)
• Certificate of compliance with European Pharmacopoeia (COS)
• Food and Drug Administration authorization (FDA).

Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.

We have offices across 24 countries in Europe and North America, we export to over 50 countries worldwide and have six manufacturing sites. The Dechra Group employ over one thousand people and our revenue in 2018 reached £407.1m.

Our six Dechra Values: Dedication, Enjoyment, Courage, Honesty, Relationships and Ambition reflect the best aspects of behaviour and competence in Dechra. We embrace the values at every level of the business and everything about the business is underpinned by our values. How we talk to the people that matter, the way we always look to do things better and how we think of the people and the animals beyond the product.

We are active in Companion Animal, Equine and Food Producing Animal products.

Our key focus therapeutic areas are:
• Endocrinology
• Dermatology
• Anaesthesia and Analgesia
• Water Medication
• Diets and Nutrition
• Equine Locomotion

And we support our clients in practice with a wide range of materials and technical advice.

Follow us on Twitter - @Dechra

Humabs BioMed, a Subsidiary of Vir Biotechnology Inc., is a leading Swiss antibody therapeutics company that discovers and develops superior monoclonal antibodies directly derived from individuals whose immune system has successfully responded to major diseases. The company currently focuses on infectious diseases, but also has selected antibodies against inflammatory diseases and cancer in the pipeline.